Overview
SLU-PP-332 is a potent synthetic agonist for the estrogen-related receptor (ERR) family, specifically ERRa, ERRb, and ERRg. These nuclear receptors are master regulators of mitochondrial biogenesis and oxidative metabolism. Their activation has been studied as a molecular mechanism underlying endurance exercise adaptation.
Key Research Areas
- Exercise Mimetic Research: ERRa and ERRg control gene expression programs activated by endurance training. Published in Nature Communications (2023), SLU-PP-332 was shown to upregulate OXPHOS genes and increase running endurance in animal models without physical training.
- Mitochondrial Biogenesis: Acts upstream of PGC-1a to drive mitochondrial number and function – studied in ageing, metabolic disease, and heart failure models.
- AMPK Pathway Activation: Demonstrated activation of AMPK leading to increased fatty acid oxidation and decreased lipid accumulation in muscle cells.
- Cardiac Research: ERRa and ERRg are highly expressed in cardiomyocytes; studied in heart failure models for effects on cardiac energy metabolism.
- Metabolic Syndrome Models: Increased fatty acid oxidation and reduced adipogenesis make it a subject in obesity mechanism research.
Specifications
- CAS: 2387713-37-1
- Purity: ≥99% (HPLC verified)
- Form: Capsules (microcrystalline cellulose carrier)
- Quantity: 60 capsules x 250 mcg
For in vitro laboratory research use only. Not for human or animal administration.
Reviews
There are no reviews yet.